Gufic BioSciences Ltd (GUFICBIO)
₹413.55
Mkt cap
₹4,147 Cr
P/E ratio
56.40
P/B
6.25
Div yield
0.02%
ROE
9.98%
ROCE
12.20%
EPS (TTM)
₹7.33
Book value
₹66
52W range
268–468
Sector
Healthcare
Price history
Previous close
Gufic Biosciences Limited is engaged in the manufacture of pharmaceuticals, medicinal chemicals and botanical products.
NSE GUFICBIOBSE 509079
Health check
Mixed
ValuationExpensive
ProfitabilityAverage
GrowthHigh
TechnicalsNeutral
52-week range
−11.60% from high₹414
₹268+54.31% from low₹468
Current
₹413.55
Prev close
₹418.80
Day
−1.25%
Price performance
1D
−1.38%
1W
+5.41%
1M
−5.38%
3M
+7.57%
6M
+42.78%
1Y
+19.94%
YTD
+22.72%
Financials
Revenue, profit & margin
P/E ratio
56.4×
GUFICBIO is 64% above the sector median of 34.4×
GUFICBIO56.4×
Sector median34.4×
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 195 | 215 | 202 | 195 | 203 | 204 | 208 | 205 | 227 | 230 | 231 | 252 | 261 | |
| Expenses | 160 | 176 | 165 | 161 | 167 | 166 | 174 | 178 | 195 | 195 | 195 | 206 | 214 | |
| Operating Profit | 35 | 39 | 36 | 34 | 36 | 39 | 34 | 27 | 32 | 36 | 36 | 46 | 47 | |
| OPM % | 18% | 18% | 18% | 18% | 18% | 19% | 16% | 13% | 14% | 16% | 16% | 18% | 18% | |
| Other Income | 1 | 0 | 0 | 1 | 1 | 0 | 2 | 0 | 1 | 2 | 1 | -1 | 0 | |
| Interest | 4 | 4 | 3 | 4 | 5 | 5 | 5 | 8 | 9 | 10 | 8 | 9 | 9 | |
| Depreciation | 4 | 4 | 4 | 4 | 4 | 4 | 5 | 8 | 8 | 8 | 8 | 8 | 8 | |
| Profit before tax | 28 | 31 | 30 | 27 | 28 | 29 | 26 | 11 | 16 | 21 | 21 | 28 | 30 | |
| Tax % | 26% | 25% | 25% | 26% | 26% | 26% | 26% | 26% | 26% | 27% | 26% | 26% | 26% | |
| Net Profit | 21 | 23 | 22 | 20 | 21 | 22 | 19 | 8 | 12 | 15 | 16 | 21 | 22 | |
| EPS in Rs | 2.13 | 2.39 | 2.22 | 2.00 | 2.08 | 2.17 | 1.93 | 0.79 | 1.20 | 1.49 | 1.55 | 2.05 | 2.24 | |
| Raw PDF |
Earnings
Results dates & reactionsNo upcoming results date on calendar.
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
Avg earnings-day move −0.95% · closed higher next day 0 of last 1
| Q1FY27 | |
|---|---|
| Broadcast | 14 Aug '26◦ |
| Earnings day | −0.95% |
| +1 day | −0.19% |
| +5 days | −0.99% |
| +15 days | +6.11% |
| +30 days | +3.39% |
| Filing |
Corporate actions
Last 6 monthsNo recent corporate actions
Dividends, splits, and bonuses in the last six months show up here.
Shareholding
as of Sep 202672.50%Promoter
Promoters72.50%
FIIs0.44%0.03
DIIs3.38%0.29
Public23.66%0.30
Ownership trend
Peers
8 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| Sun Pharma.Inds. | ₹1,777.70 | 34.66 | 4,26,530 | 0.90% | 1,995 | −10.53% | 16,199 | +11.88% | 20.53% |
| Divi's Lab. | ₹9,780.00 | 87.14 | 2,59,628 | 0.31% | 902 | +65.50% | 3,080 | +27.80% | 21.97% |
| Torrent Pharma. | ₹4,613.40 | 80.83 | 1,75,479 | 0.82% | 534 | −10.03% | 4,979 | +50.79% | 15.19% |
| Laurus Labs | ₹2,405.50 | 97.00 | 1,29,972 | 0.08% | 436 | +126.43% | 2,206 | +33.44% | 17.76% |
| Zydus Lifesci. | ₹1,245.50 | 25.52 | 1,24,239 | 0.08% | 990 | −35.09% | 8,017 | +21.96% | 21.14% |
| Dr Reddy's Labs | ₹1,352.00 | 40.30 | 1,12,849 | 0.59% | 913 | −31.35% | 8,698 | −1.48% | 13.04% |
| Cipla | ₹1,378.90 | 35.87 | 1,11,397 | 0.94% | 852 | −35.05% | 7,404 | −2.44% | 15.49% |
| Gufic BioScience | ₹413.55 | 56.40 | 4,147 | 0.02% | 22 | +86.08% | 261 | +14.94% | 12.17% |
| Median: 158 Co. | ₹426.38 | 34.39 | 1,921 | 0.08% | 14 | +22.08% | 175 | +18.92% | 15.12% |
Filings
Annual reports15
Concall transcripts51
TranscriptAug 2026PPTAug 2026RECAug 2026TranscriptJun 2026PPTJun 2026RECJun 2026TranscriptFeb 2026PPTFeb 2026RECFeb 2026TranscriptNov 2025PPTNov 2025RECNov 2025TranscriptAug 2025PPTAug 2025TranscriptJun 2025PPTJun 2025RECMay 2025TranscriptFeb 2025PPTFeb 2025TranscriptNov 2024PPTNov 2024RECNov 2024TranscriptAug 2024PPTAug 2024
Credit ratings6
Announcements5
Intimation Regarding USFDA Pre-Approval Inspection At The Company'S Manufacturing Facility Situated At Indore, Madhya Pradesh 23 Oct - USFDA conducted pre-approval inspection at Indore facility from Oct 15-23, 2026; received 3 observations.Announcement under Regulation 30 (LODR)-Newspaper Publication 17 Oct - Newspaper Advertisement regarding Special Window for Re-lodgement of Transfer and Dematerialization of physical sharesCompliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 6 Oct - Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended September 30, 2026 is attached herewithIntimation Under Regulation 30 Of The SEBI (LODR) Regulations, 2015 29 Sep - CIT(A) allowed Gufic’s appeal, deleting Rs. 4.33 crore AY2024-25 income tax demand.Closure of Trading Window 28 Sep